Robyn Lorraine Woods

Prof. Dr. Robyn Lorraine Woods

orcid

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 April 2019 in Clinical Epigenetics
Verified
Journal Article
Open access
PDF file
PFPeter Daniel Fransquet
Peter Daniel Fransquet
JWJo Wrigglesworth
Jo Wrigglesworth
RWRobyn Lorraine Woods
Robyn Lorraine Woods
MEMichael E. Ernst
Michael E. Ernst
JRJoanne Ryan
Joanne Ryan
Ageing is one of the principal risk factors for many chronic diseases. However, there is considerable between-person variation in the rate of ageing and individual differences in their susceptibility to disease and death. Epigenetic mechanisms may play a role in human ageing, and DNA methylation age biomarkers may be good predictors of age-related diseases and mortality risk. The aims of this systematic review were to identify and synthesise the evidence for an association between peripherally measured DNA methylation age and longevity, age-related disease, and mortality risk. A systematic search was conducted in line with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. Using relevant search terms, MEDLINE, Embase, Cochrane Central Register of Controlled Trials, and PsychINFO databases were searched to identify articles meeting the inclusion criteria. Studies were assessed for bias using Joanna Briggs Institute critical appraisal checklists. Data was extracted from studies measuring age acceleration as a predictor of age-related diseases, mortality or longevity, and the findings for similar outcomes compared. Using Review Manager 5.3 software, two meta-analyses (one per epigenetic clock) were conducted on studies measuring all-cause mortality. Twenty-three relevant articles were identified, including a total of 41,607 participants. Four studies focused on ageing and longevity, 11 on age-related disease (cancer, cardiovascular disease, and dementia), and 11 on mortality. There was some, although inconsistent, evidence for an association between increased DNA methylation age and risk of disease. Meta-analyses indicated that each 5-year increase in DNA methylation age was associated an 8 to 15% increased risk of mortality. Due to the small number of studies and heterogeneity in study design and outcomes, the association between DNA methylation age and age-related disease and longevity is inconclusive. Increased epigenetic age was associated with mortality risk, but positive publication bias needs to be considered. Further research is needed to determine the extent to which DNA methylation age can be used as a clinical biomarker.

20 January 2017 in The Journals of Gerontology, Series A: Biological Sciences and Medical Sciences
Verified
Journal Article
Closed access
PDF file
JMJohn McNeil
John McNeil
RWRobyn Lorraine Woods
Robyn Lorraine Woods
MNMark R Nelson
Mark R Nelson
AMAnne M Murray
Anne M Murray
CRChristopher M Reid
Christopher M Reid
AGASPREE Investigator Group
ASPREE Investigator Group
There are no primary prevention trials of aspirin with relevant geriatric outcomes in elderly people. ASPirin in Reducing Events in the Elderly (ASPREE) is a placebo-controlled trial of low-dose aspirin that will determine whether 5 years of daily 100-mg enteric-coated aspirin extends disability-free and dementia-free life in a healthy elderly population and whether these benefits outweigh the risks. Set in primary care, this randomized double-blind placebo-controlled trial has a composite primary endpoint of death, incident dementia or persistent physical disability. Participants aged 70+ years (non-minorities) or 65+ years (U.S. minorities) were free of cardiovascular disease, dementia, or physical disability and without a contraindication to, or indication for, aspirin. Baseline data include physical and lifestyle, personal and family medical history, hemoglobin, fasting glucose, creatinine, lipid panel, urinary albumin:creatinine ratio, cognition (3MS, HVLT-R, COWAT, SDMT), mood (CES-D-10), physical function (gait speed, grip strength), Katz activities of daily living and quality of life (SF-12). Recruitment ended in December 2014 with 16,703 Australian and 2,411 U.S. participants, a median age of 74 (range 65–98) years and 56% women. Approximately 55% of the U.S. cohort were from minority groups; 9% of the total cohort. Proportions with hypertension, overweight, and chronic kidney disease were similar to age-matched populations from both countries although lower percentages had diabetes, dyslipidemia, and osteoarthritis. Findings from ASPREE will be generalizable to a healthier older population in both countries and will assess whether the broad benefits of daily low-dose aspirin in prolonging independent life outweigh the risks.

13 December 2021 in BMC Geriatrics
Verified
Journal Article
Open access
PDF file
RFRosanne Freak-Poli
Rosanne Freak-Poli
JRJoanne Ryan
Joanne Ryan
JNJohannes Tobias Neumann
Johannes Tobias Neumann
ATAndrew M. Tonkin
Andrew M. Tonkin
CRChristopher M. Reid
Christopher M. Reid
Alice OwenAlice Owen
Alice Owen
Background: Poor social health is associated with increased risk of cardiovascular disease (CVD). Recent research suggests that different social health domains should be considered separately as the implications for health and possible interventions may differ. Aim: To assess social isolation, low social support and loneliness as predictors of CVD. Methods: Secondary analysis of 11,486 community-dwelling, Australians, aged 70 years and over, free of CVD, dementia, or significant physical disability, from the ASPirin in Reducing Events in the Elderly (ASPREE) trial. Social isolation, social support (Revised Lubben Social Network Scale), and loneliness were assessed as predictors of CVD using Cox proportional-hazard regression. CVD events included fatal CVD, heart failure hospitalization, myocardial infarction and stroke. Analyses were adjusted for established CVD risk factors. Results: Individuals with poor social health were 42 % more likely to develop CVD (p = 0.01) and twice as likely to die from CVD (p = 0.02) over a median 4.5 years follow-up. Interaction effects indicated that poorer social health more strongly predicted CVD in smokers (HR 4.83, p = 0.001, p-interaction = 0.01), major city dwellers (HR 1.94, p < 0.001, p-interaction=0.03), and younger older adults (70-75 years; HR 2.12, p < 0.001, p-interaction = 0.01). Social isolation (HR 1.66, p = 0.04) and low social support (HR 2.05, p = 0.002), but not loneliness (HR 1.4, p = 0.1), predicted incident CVD. All measures of poor social health predicted ischemic stroke (HR 1.73 to 3.16). Conclusions: Among healthy older adults, social isolation and low social support may be more important than loneliness as cardiovascular risk factors. Social health domains should be considered in future CVD risk prediction models.

11 August 2020 in JNCI: Journal of the National Cancer Institute
Verified
Journal Article
Open access
PDF file
JMJohn McNeil
John McNeil
PGPeter Gibbs
Peter Gibbs
Suzanne G OrchardSuzanne G Orchard
Suzanne G Orchard
JLJessica E Lockery
Jessica E Lockery
WBWendy B Bernstein
Wendy B Bernstein
TGthe ASPREE Investigator Group
the ASPREE Investigator Group
Background: ASPirin in Reducing Events in the Elderly, a randomized, double-blind, placebo-controlled trial of daily low-dose aspirin (100 mg) in older adults, showed an increase in all-cause mortality, primarily due to cancer. In contrast, prior randomized controlled trials, mainly involving younger individuals, demonstrated a delayed cancer benefit with aspirin. We now report a detailed analysis of cancer incidence and mortality. Methods: 19 114 Australian and US community-dwelling participants aged 70 years and older (US minorities 65 years and older) without cardiovascular disease, dementia, or physical disability were randomly assigned and followed for a median of 4.7 years. Fatal and nonfatal cancer events, a prespecified secondary endpoint, were adjudicated based on clinical records. Results: 981 cancer events occurred in the aspirin and 952 in the placebo groups. There was no statistically significant difference between groups for all incident cancers (hazard ratio [HR] = 1.04, 95% confidence interval [CI] = 0.95 to 1.14), hematological cancer (HR = 0.98, 95% CI = 0.73 to 1.30), or all solid cancers (HR = 1.05, 95% CI = 0.95 to 1.15), including by specific tumor type. However, aspirin was associated with an increased risk of incident cancer that had metastasized (HR = 1.19, 95% CI = 1.00 to 1.43) or was stage 4 at diagnosis (HR = 1.22, 95% CI = 1.02 to 1.45), and with higher risk of death for cancers that presented at stages 3 (HR = 2.11, 95% CI = 1.03 to 4.33) or 4 (HR = 1.31, 95% CI = 1.04 to 1.64). Conclusions: In older adults, aspirin treatment had an adverse effect on later stages of cancer evolution. These findings suggest that in older persons, aspirin may accelerate the progression of cancer and, thus, suggest caution with its use in this age group.

20 October 2021 in Neurobiology of Aging
Verified
Journal Article
Closed access
JWJo Wrigglesworth
Jo Wrigglesworth
NYNurathifah Yaacob
Nurathifah Yaacob
PWPhillip Ward
Phillip Ward
RWRobyn Lorraine Woods
Robyn Lorraine Woods
JMJohn McNeil
John McNeil
JRJoanne Ryan
Joanne Ryan

28 November 2023 in Neurology
Verified
Journal Article
Closed access
PDF file
ZZZhen Zhou
Zhen Zhou
JRJoanne Ryan
Joanne Ryan
ATAndrew M. Tonkin
Andrew M. Tonkin
SZSophia Zoungas
Sophia Zoungas
PLPaul Lacaze
Paul Lacaze
MNMark Nelson
Mark Nelson
Background and Objectives: It has been suggested that higher triglyceride levels were associated with a lower risk of Alzheimer9s disease. This study aimed to examine the association of triglycerides with dementia and cognition change in community-dwelling older adults. Methods: This prospective longitudinal study used data from the ASPREE randomized trial of adults aged ≥65 years without dementia or previous cardiovascular events at enrolment. The main outcome was incident dementia. Other outcomes included changes in composite cognition and domain-specific cognition (global cognition, memory, language and executive function, and psychomotor speed). The association between baseline triglycerides and dementia risk was estimated using Cox proportional-hazard models adjusting for relevant risk factors. Linear mixed models were used to investigate cognitive change. The analysis was repeated in a sub-cohort of participants with available APOE-ε4 genetic data with additional adjustment for APOE-ε4 carrier status, and an external cohort (UK Biobank) with similar selection criteria applied. Results: The study included 18,294 ASPREE participants and 68,200 UK Biobank participants (mean age: 75.1 & 66.9 years; female: 56.3% & 52.7%; median [IQR] triglyceride:106 [80-142]mg/dl & 139 [101-193]mg/dl), with dementia recorded in 823 and 2,778 individuals over a median follow-up of 6.4 and 12.5 years, respectively. Higher triglyceride levels were associated with lower dementia risk in the entire ASPREE cohort (HR with doubling of TG: 0.82, 95% CI 0.72-0.94). Findings were similar in the sub-cohort of participants with APOE-ε4 genetic data (n=13,976), and in the UK Biobank cohort (HR was 0.82 and 0.83, respectively, all p≤0.01). Higher triglycerides were also associated with slower decline in global, composite cognition, and memory over time (p≤0.05). Discussion: Older adults with higher triglyceride levels within the normal to high-normal range had a lower dementia risk and slower cognitive decline over time compared to individuals with lower triglyceride levels. Higher triglyceride levels may be reflective of better overall health and/or lifestyle behaviors that would protect against dementia development. Future studies are warranted to investigate whether specific components within the total circulating pool of plasma triglycerides may promote better cognitive function, with the hope of informing the development of new preventive strategies.